

Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States

SUPPLEMENTAL DIGITAL CONTENT

SUPPLEMENTAL TABLE 1. Length of Liposomal Irinotecan Therapy			
Category	n	Days, Median (IQR)	P
Overall	257	51 (24–120)	
Treatment line			
First/second line	145	62 (22–133)	0.027
Third line or later	112	44.5 (24–85)	
Dose at initiation			
Initiated at low dose	67	50 (15–94)	0.831
Initiated at indicated dose	152	57 (24–128)	
Initiated at high dose	11	43 (15–170)	
Initial administration had missing data	27	71 (32–113)	
Dose intensity			
Below median dose intensity	115	22 (1–57)	<0.0001
At or above median dose intensity	116	92 (49.5–169)	
Dose modification			
Modified dose	70	92 (50–174)	<0.0001
Did not modify dose	187	43 (15–94)	
IQR indicates interquartile range.			